Exosomes: the decoy receptors that may sabotage lymphoma treatment
NCT ID NCT03985696
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By analyzing blood samples from patients and healthy volunteers, the team hopes to understand how exosomes contribute to treatment resistance and whether they could serve as early warning signs of poor outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal why some lymphomas stop responding to immunotherapy and point toward new ways to overcome that resistance.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings from lab experiments may not translate to real-world patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Limoges
Limoges, 87042, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers